


10048225.073102
JC07 Rec'd PCT/PTO 29 JAN 2002



TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. § 371

Attorney's Docket Number

056222-5009

U.S. Application No.

10/048225

Unassigned

International Application No.

International Filing Date

Priority Date Claimed

PCT/GB00/02962

July 31, 2000

July 29, 1999

Title of Invention: METHOD FOR DETECTING NUCLEIC ACID TARGET SEQUENCES INVOLVING
VITRO TRANSCRIPTION FROM AN RNA POLYMERASE PROMOTOR

Applicants For EO/EO/US: John Scott LLOYD, Anthony WESTON and Donald Leonard Nicholas CARDY

Applicants herewith submit to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a FIRST submission of items concerning a filing under 35 U.S.C. § 371.
2. ☐ This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. § 371.
3. ☐ This express request to begin national examination procedures (35 U.S.C. § 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. § 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. § 371(c)(2))
 - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☒ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ A translation of the International Application into English (35 U.S.C. § 371(c)(2)).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. § 371(c)(3)).
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. § 371(c)(3)).
9. ☐ An oath or declaration of the inventors (35 U.S.C. § 371(c)(4)).
10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. § 371(c)(5)).

Items 11. to 14. below concern other document(s) or information included:

11. ☒ An Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 C.F.R. § 3.28 and § 3.31 is included.
13. ☒ A FIRST preliminary amendment.
14. ☒ A SECOND or SUBSEQUENT preliminary amendment.
- Other items or information:
 - a. PCT/IB/304
 - b. PCT/IB/308
 - c. PCT/IPEA/409
 - d. Statement Accompanying Sequence Listing
 - e. Diskette containing Sequence Listing CRF
 - f. Paper Copy of Sequence Listing

U.S. APPLICATION NO. | INTERNATIONAL APPLICATION NO. | ATTORNEY DOCKET NUMBER

10/048225

PCT/GB00/02962

1056222-5009

15. ☒ The following fees are submitted:
Basic National Fee (37 C.F.R. § 1.492(a)(1)-(5)):
 Search Report has been prepared by the EPO or JPO.....\$890.00
 International preliminary examination fee paid to
 USPTO (37 C.F.R. § 1.482).....\$710.00
 No international preliminary examination fee paid to
 USPTO (37 C.F.R. § 1.482) but international search fee
 paid to USPTO (37 C.F.R. § 1.445(a)(2)).....\$740.00
 Neither international preliminary examination fee
 (37 C.F.R. § 1.482) nor international search fee
 (37 C.F.R. § 1.445(a)(2)) paid to USPTO.....\$1,040.00
 International preliminary examination fee paid to USPTO
 (37 C.F.R. § 1.482) and all claims satisfied provisions
 of PCT Article 33(2)-(4).....\$100.00

ENTER APPROPRIATE BASIC FEE AMOUNT = \$890.00

Surcharge of \$130.00 for furnishing the oath or declaration later than

☐ 20 ☒ 30 months from the earliest claimed priority date

(37 C.F.R. § 1.492(e)).

Claims	Number Filed	Number Extra	Rate	
Total Claims	17 - 20 =	0	X \$18.00	\$
Independent Claims	3 - 3 =	0	X \$84.00	\$
Multiple dependent claim(s) (if applicable)			+ \$280.00	\$
TOTAL OF ABOVE CALCULATIONS				\$
Reduction by ½ for filing by small entity, if applicable.				-\$445.00
SUBTOTAL =				\$ 445.00
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 C.F.R. § 1.492(f)).				+\$
TOTAL NATIONAL FEE =				\$445.00
Fee for recording the enclosed assignment (37 C.F.R. § 1.21(h)). The Assignment must be accompanied by an appropriate cover sheet (37 C.F.R. §§ 3.28, 3.31). \$40.00 per property				\$
TOTAL FEES ENCLOSED =				\$
Amount to be refunded				\$
Amount to be charged				\$445.00

- a. ☐ A check in the amount of \$_____ to cover the above fees is enclosed.
 b. ☒ Please charge my Deposit Account No. 50-0310 in the amount of \$445.00 to cover the above fees. A duplicate copy of this sheet is enclosed.
 c. ☒ **Except** for issue fees payable under 37 C.F.R. § 1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. § 1.16 and § 1.17 which may be required, or credit any overpayment to Deposit Account No. 50-0310.

Customer No. 09629

SEND ALL CORRESPONDENCE TO:

Morgan, Lewis & Bockius LLP
 1111 Pennsylvania Avenue N.W.
 Washington, D.C. 20004
 Telephone: (202) 739-3000
 Facsimile: (202) 739-3001

Elizabeth C. Weimar
 Elizabeth C. Weimar
 Reg. No. 44,478

Submitted: January 29, 2002

PATENT
Attorney Docket No. 056222-5009

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of : John Scott LLOYD, et al.)	
)	Group Art Unit: Unassigned
U.S. National Phase Application)	
Filed: January 29, 2002)	Examiner: Unassigned
)	
U.S. Application No.: To Be Assigned)	
)	
Date of National)	
Stage Entry : Concurrently)	
)	
Based on PCT/GB00/02962)	
Filed : July 31, 2000)	
)	
For: METHOD FOR DETECTING NUCLEIC)	
ACID TARGET SEQUENCES)	
INVOLVING IN VITRO)	
TRANSCRIPTION FROM AN RNA)	
POLYMERASE PROMOTER)	

Commissioner for Patents
Washington, D.C. 20231

Sir:

PRELIMINARY AMENDMENT

Prior to the examination of the above-identified application on the merits, please amend the application as follows:

IN THE CLAIMS:

Please substitute the following amended versions of claims 4, 5, 8-11, 13-15 and 17 for the corresponding original claims.

4. (Amended) A complex according claim 1, comprising a functional double stranded T3, T7 or SP6 RNA polymerase promoter.

Attorney Docket No.: 056222-5009

Application No.: Unassigned

5. (Amended) A complex according to claim 1, comprising single or double stranded sequence adjacent to the promoter which increases the activity of the promoter.

8. (Amended) A complex according to claim 1, comprising a sequence which, when transcribed into RNA, facilitates isolation, identification, detection, quantification or amplification of the transcript.

9. (Amended) A complex according claim 1, wherein one of said probes comprises a destabilizing moiety.

10. (Amended) A complex according to claim 1, wherein the second and third probes form a discontinuous sequence of an RNA polymerase promoter template strand.

11. (Amended) A complex according to claim 1, wherein the second and third probes form a discontinuous sequence of an RNA polymerase promoter non-template strand.

13. (Amended) A method according to claim 12, performance of which results in the formation of a complex in accordance with claim 1.

14. (Amended) A method according to claim 12, wherein RNA produced from the functional RNA promoter is amplified prior to detection.

15. (Amended) A method according to claim 12, wherein RNA produced from the functional RNA promoter is detected directly or indirectly via a method which involves use of a molecular beacon or fluorophore.

Attorney Docket No.: 056222-5009

Application No.: Unassigned

17. (Amended) A method of detecting in a sample the presence of a nucleic acid target sequence, comprising the steps of :

contacting a first probe and a second probe with the sample so as to form the complex of claim 16, wherein the first probe comprises in the 5' to 3' direction, a template portion transcribable by an RNA polymerase, a template strand of an RNA polymerase promoter, and a target complimentary portion which is hybridised to at least a 3' end region of the target sequence, and the second probe comprises part of the non-template strand complimentary to the template strand of the promoter present in the first probe;

and, detecting directly or indirectly RNA transcripts of the template portion of the first probe.

1000442225 07 23 02
Attorney Docket No.: 056222-5009
Application No.: Unassigned

REMARKS

Applicants respectfully submit that no prohibited new matter has been introduced by this Preliminary Amendment and that amended claims 4,5, 8-11, 13-15 and 17 are drawn to the same invention as the corresponding claims of International Application PCT/GB00/02962. The changes to the claims represent changes in formalities so as to bring the claims into compliance with the rules of practice in the United States, by avoiding improper multiple dependencies and eliminating multiple dependencies to reduce costs.

Respectfully Submitted,

MORGAN, LEWIS & BOCKIUS LLP

By: Elizabeth C. Weimar
Elizabeth C. Weimar
Reg. No. 44,478

Date: January 29, 2002

CUSTOMER NO. 009629
MORGAN, LEWIS & BOCKIUS LLP
1111 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
(202) 739-3000 (Telephone)
(202) 739-3001 (Fax)

Attorney Docket No. 056222-5009

MARKED-UP VERSION TO SHOW CHANGES IN CLAIMS

4. **(Amended)** A complex according to ~~[to any one of claims 1, 2 or 3]~~ **claim 1**, comprising a functional double stranded T3, T7 or SP6 RNA polymerase promoter.

5. **(Amended)** A complex according to ~~[any of the preceding claims]~~ **claim 1**, comprising single or double stranded sequence adjacent to the promoter which increases the activity of the promoter.

8. **(Amended)** A complex according to **claim 1** ~~[any one of the preceding claims]~~, comprising a sequence which, when transcribed into RNA, facilitates isolation, identification, detection, quantification or amplification of the transcript.

9. **(Amended)** A complex according to ~~[any one of the preceding claims]~~ **claim 1**, wherein one of said probes comprises a destabilizing moiety.

10. **(Amended)** A complex according to ~~[any one of the preceding claims]~~ **claim 1**, wherein the second and third probes form a discontinuous sequence of an RNA polymerase promoter template strand.

11. **(Amended)** A complex according to ~~[any one of claims 1-9]~~ **claim 1**, wherein the second and third probes form a discontinuous sequence of an RNA polymerase promoter non-template strand.

13. **(Amended)** A method according to claim 12, performance of which results in the formation of a complex in accordance with ~~[any one of claims 1-11]~~ **claim 1**.

14. (Amended) A method according to claim 12 ~~[or 13]~~, wherein RNA produced from the functional RNA promoter is amplified prior to detection.

15. (Amended) A method according to ~~[any one of claims]~~ **claim 12**, ~~[13 or 14]~~, wherein RNA produced from the functional RNA promoter is detected directly or indirectly via a method which involves use of a molecular beacon or fluorophore.

17. (Amended) A method of detecting in a sample the presence of a nucleic acid target sequence~~;~~ ~~the method~~, comprising the steps of:

contacting a first **probe** and a second probe ~~[as defined above]~~ with the sample~~;~~ so as to form the complex of claim 16~~;~~ ~~and~~, **wherein the first probe comprises in the 5' to 3' direction, a template portion transcribable by an RNA polymerase, a template strand of an RNA polymerase promoter, and a target complimentary portion which is hybridised to at least a 3' end region of the target sequence, and the second probe comprises part of the non-template strand complimentary to the template strand of the promoter present in the first probe;**

and, detecting directly or indirectly RNA transcripts of the template portion of the first probe.

**METHOD FOR DETECTING NUCLEIC ACID TARGET SEQUENCES
INVOLVING IN VITRO TRANSCRIPTION FROM AN RNA POLYMERASE
PROMOTER**

Field of the Invention

This invention relates to nucleic acid complexes comprising a functional RNA polymerase promoter, and to a method of detecting a target nucleic acid sequence of interest.

Background of the Invention

RNA polymerases are enzyme molecules well-known to those skilled in the fields of molecular biology and molecular diagnostic kits. RNA polymerases synthesise RNA molecules from a DNA template strand.

Much research has been carried out on RNA polymerases, especially bacteriophage RNA polymerases.

Specifically, the RNA polymerase from the bacteriophage T7 has been shown to be very selective for specific promoters that are rarely encountered in DNA unrelated to T7 DNA (Chamberlin *et al*, 1970 Nature **228**, 227; Dunn & Studier 1983 J. Mol. Biol. **166**, 477). T7 RNA polymerase is able to make complete transcripts of almost any DNA that is placed under control of a T7 promoter. T7 RNA polymerase is a highly active enzyme that transcribes about five times faster than does *Escherichia coli* RNA polymerase (Studier *et al*, 1990 Methods Enzymol. **185**, 60). The synthesis of small RNAs using T7 RNA polymerase has been described whereby sequences around the RNA polymerase promoter sequence are shown to be important in the reproducible improvement of yield of RNA produced (Milligan & Uhlenbeck, 1989 Methods Enzymol. **180**, 51 and Milligan *et al*, 1987 Nucl. Acids Res. **15**, 8783-8798). Other RNA polymerases that have similar properties to T7 include those from bacteriophage T3 and SP6, the genes for which have all been cloned and the corresponding enzymes are commercially available. The optimum promoter sequences for T7, T3 and SP6 polymerases are known, and are essentially 17 nucleotides long.

A number of methods have been disclosed, which utilise RNA polymerases to synthesise RNA directly or indirectly as the result of the presence of a particular nucleic acid sequence of interest ("target"). The presence of RNA (detected directly or indirectly) thus serves to signal the presence of the sequence of interest and can be used as the basis of assay methods and/or diagnostic methods or kits. Examples include the disclosures of WO 93/06240, WO 94/29481, EP 0851033, and EP 0552931.

In particular WO 93/06240 discloses the use of two probes, which hybridise together only in the presence of a target nucleic acid sequence of interest, such that hybridisation of the probes to each other is indicative of the presence of the sequence of interest.

All publications mentioned in this specification are incorporated herein by reference.

Summary of the Invention

In a first aspect the invention provides a complex formed by a hybridisation reaction comprising four nucleic acid molecules; the complex comprising a target nucleic acid molecule and first, second and third nucleic acid probe molecules; wherein the first probe comprises a foot region which is complementary to a first portion of the target and is hybridised thereto, and an arm region which is substantially non-complementary to the target; the second probe comprises a foot region which is complementary to a second portion of the target, such that the foot region of the second probe is hybridised to the target adjacent or substantially adjacent to the foot region of the first probe, the second probe also comprising an arm region which is substantially non-complementary to the target but which is complementary and hybridised to the arm region of the first probe; the third probe being complementary, at least in part, to a portion of the arm region of the first probe, such that the third probe is hybridised to the arm region of the first probe adjacent or substantially adjacent to the second probe; and wherein formation of the complex creates a functional double-stranded RNA polymerase promoter, one strand of the promoter being provided by the first probe, and the other strand being provided jointly by the second probe and by the third probe.

Preferably the sequence of the probes and the hybridisation reaction conditions are selected such that the first and second probes cannot become hybridised in the absence of the target, such that formation of the RNA polymerase promoter occurs in a target-dependent manner.

In a second aspect, the invention provides a method of detecting the presence of a target nucleic acid molecule in a sample, the method comprising the steps of contacting the sample comprising the target with first and second nucleic acid probes, each probe comprising a foot region complementary to respective first and second portions of the target, which portions are adjacent or substantially so; wherein the first and second probes each further comprise an arm region substantially non-complementary to the target, at least part of the arm region of the first probe being complementary to at least part of the arm region of the second probe, such that respective foot regions of the first and second probes hybridise to the target, allowing hybridisation of the complementary parts of the arm regions of the first and second probes; and causing to be present a third nucleic acid probe molecule which is complementary to a portion of the arm region of the first probe, such that the third probe hybridises to the first probe adjacent or substantially adjacent to the arm region of the second probe, thereby creating a functional double-stranded RNA polymerase promoter, one strand of the promoter being provided by the first probe, the other strand being provided jointly by the second and third probes; causing RNA synthesis from the RNA promoter; and detecting, directly or indirectly, the RNA so synthesised.

The method of the second aspect of the invention thus results in formation of the complex of the first aspect.

It is an essential feature of the invention that the first and second probes, when hybridised to the target sequence, are adjacent or substantially adjacent to each other. Use of the term "adjacent" is herein intended to mean that there are no nucleotides of the target sequence left without base-pairing between those portions of the target sequence which are base-paired to the complementary sequence of the probes. This proximity between the probes

enables the complementary arm portions of the probes to anneal. As will readily be apparent to those skilled in the art, by designing the probes so as to allow for annealing to each other at greater separations from the target sequence, gaps may be introduced between the loci in the target nucleotide sequence to which the probes hybridise. In this situation the probes are said to be "substantially adjacent", because there may be some nucleotides of the target sequence left without base-pairing between those portions of the target sequence which are base-paired to the probes. Clearly, the number of intervening un-paired nucleotides of the target sequence can vary according to the design of the probes. Thus whilst it is preferred that the first and second probes hybridise so as to be adjacent, the probes may be separated by up to 5 nucleotides of target sequence, and the term "substantially adjacent" is intended to refer to such situations.

It will also be appreciated from the foregoing that the second and third probes must hybridise to the arm region of the first probe such that the second and third probes are "adjacent", or substantially so, which terms are intended to have the same meanings as defined above. However, as the second and third probes together constitute one strand of the promoter, it is very much to be desired that they hybridise in an adjacent manner so as to provide optimum promoter activity: the inventors have found that the amount of promoter activity is greatly reduced even if a single nucleotide gap occurs between the second and third probes.

It will be apparent to those skilled in the art that the order of addition of probes in the formation of the nucleic acid complex is not critical: the third probe may, for example, be hybridised to the first probe before the second probe and sample are added. Alternatively, for example, all three probes may be simultaneously mixed with the sample containing the target molecule.

It will be further apparent to those skilled in the art that the second and third probes, which jointly provide one of the strands of the RNA polymerase promoter, are not covalently joined and the promoter sequence thus contains a "nick" in the phosphodiester backbone of one of the strands. For the sake of clarity, it is mentioned that the aforementioned first,

second and third probes are elsewhere described and referred to in this specification as "template", "complement" and "split complement" respectively.

Preferred promoters for use in the invention are those recognised by bacteriophage polymerases, especially those promoters recognised by one of T3, T7 or SP6 polymerase. These will generally comprise a minimum of 17 or 18 bases, essentially double-stranded. The sequence of the double-stranded T3 RNA polymerase promoter (described in the prior art) is:

- i) 5' AATTAACCCTCACTAAA 3'
3' TTAATTGGGAGTGATTT 5'
- or
- ii) 5' TTA TTA ACC CTC ACT AAA 3'
3' AAT AAT TGG GAG TGA TTT 5'

i) = Seq ID No. 1

ii) = Seq ID No. 2

(A number of variant T3 promoter sequences are also known, especially those in which the first three bases of the non-template strand [the upper strand shown above] are 5' TTA 3', rather than AAT.)

The sequence of the T7 RNA polymerase promoter (described in the prior art) is:

5' TAATACGACTCACTATA 3'
3' ATTATGCTGAGTGATAT 5' (Seq ID No. 3)

The sequence of the SP6 RNA polymerase promoter (described in the prior art) is:

5' ATTTAGGTGACACTATA 3'
3' TAAATCCACTGTGATAT 5' (Seq ID No. 4)

One of the strands of the promoter is provided by the first probe. Typically this will be the "sense" (+) strand, which is transcribed by the polymerase. Accordingly the first

probe will generally comprise a stretch of "template" nucleic acid to be transcribed. The template will desirably comprise sequences which facilitate capture (e.g. hybridisation) of the resulting RNA transcript and/or detection. In addition, the first probe may desirably contain sequences (e.g. a "+12 sequence") adjacent to the promoter sequence, which serve to increase the activity of the promoter. Specific instances of such sequences are disclosed in the examples below. A "+12 sequence" is so-termed because it consists of 12 bases immediately downstream (i.e. at positions +1 to +12) of the promoter, and causes enhanced transcription levels.

The inventors have elucidated the optimum sequence of +12 regions for the T7 polymerase (discussed in greater detail below) - it is not known at present if these are also optimum for, say, T3 and SP6 polymerases. If, as is possible, SP6 and T3 polymerases have different optimum +12 regions, it would be a simple matter for the person skilled in the art to identify the relevant sequence by trial-and-error, with the benefit of the present disclosure.

The sequences of preferred +12 regions, for inclusion in the template portion of the first probe, (in respect of T7 polymerase) are shown below in Table 1. The most active +12 region (giving greatest transcription) is at the top, with the other sequences shown in decreasing order of preference.




Table 1 Alternative template +1 to +12 sequences for T7 polymerase, in descending order of transcription efficiency (Seq ID Nos. 5-14).

5' ATCGTCAGTCCC 3'
5' GCTCTCTCTCCC 3'
5' ATCCTCTCTCCC 3'
5' GTTCTCTCTCCC 3'
5' GATGTGTCTCCC 3'
5' GTTGTGTCTCCC 3'
5' ATCCTCGTGCCC 3'
5' GCTCTCGTGCCC 3'
5' GTTCTCGTGCCC 3'
5' GTTGTGGTGCCC 3'

(The 5 base is numbered as +1, being the first base downstream from the end of the promoter sequence, the 3 base as +12).

In a further embodiment, the template portion of the complex (generally on the first probe) could contain sequences that can be used to isolate, identify, detect, quantify or amplify the *de novo* synthesised RNA transcripts (see, for example, WO 93/06240, US 5,554,516, or, for example, using molecular beacon sequences such as those disclosed by Tyagi & Kramer 1996 Nature Biotech 14, 303-308). These sequences are conveniently placed adjacent to, and downstream of, a +12 region (as described above) and may comprise, but are not limited to, one or more of the following: unique "molecular beacon" sequences; capture sequences; and detection probe complementary sequences.

In principle, the seventeen bases of the promoter sequence may be partitioned between the second and third probes in any manner, provided that, in combination, the second and third probes provide one strand of the full promoter sequence. In practice, the inventors have found that optimum results are generally obtained when the second probe provides 2 to 4 (preferably 3) bases at the 5' end of the promoter sequence, with the rest of the

promoter (15 to 13 bases) being contributed by the third probe. In addition, the inventors have found that promoter activity may be enhanced by including some additional bases (typically 1-3 bases or more) at the 3' end of the third probe (e.g. by providing at least some bases complementary to the +12 sequence on the template strand, so that the +12 sequence becomes at least partially double stranded).

Any of the first, second or third probes may comprise DNA, peptide nucleic acid (PNA), locked nucleic acid (LNA), (less preferably RNA) or any combination thereof. It will, however, generally be desirable that those portions of the probes which constitute the promoter comprise conventional DNA, so as to ensure recognition by the relevant polymerase. The terms "nucleic acid complex", "nucleic acid molecule" and "nucleic acid probe" should accordingly not be construed as being limited to complexes, molecules or probes (respectively) which consist solely of conventional nucleic acid, but also encompass complexes, molecules or probes which comprise non-conventional nucleic acid (such as PNA or LNA) or non-nucleic acid portions.

PNA is a synthetic nucleic acid analogue in which the sugar/phosphate backbone is replaced by a peptide-linked chain (typically of repeated N-(2-aminoethyl)-glycine units), to which the bases are joined by methylene carbonyl linkages. PNA/DNA hybrids have high T_m values compared to double stranded DNA molecules, since in DNA the highly negatively-charged phosphate backbone causes electrostatic repulsion between the respective strands, whilst the backbone of PNA is uncharged. Another characteristic of PNA is that a single base mis-match is, relatively speaking, more destabilizing than a single base mis-match in heteroduplex DNA. Accordingly, PNA is useful to include in probes for use in the present invention, as the resulting probes have greater specificity than probes consisting entirely of DNA. Synthesis and uses of PNA have been disclosed by, for example, Orum *et al*, (1993 Nucl. Acids Res. **21**, 5332); Egholm *et al*, (1992 J. Am. Chem. Soc. **114**, 1895); and Egholm *et al*, (1993 Nature **365**, 566).

LNA is a synthetic nucleic acid analogue, incorporating "internally bridged" nucleoside analogues. Synthesis of LNA, and properties thereof, have been described by a number of authors: Nielsen *et al*, (1997 J. Chem. Soc. Perkin Trans. **1**, 3423); Koshkin *et al*, (1998

Tetrahedron Letters 39, 4381); Singh & Wengel (1998 Chem. Commun. 1247); and Singh *et al.*, (1998 Chem. Commun. 455). As with PNA, LNA exhibits greater thermal stability when paired with DNA, than do conventional DNA/DNA heteroduplexes. However, LNA can be synthesised on conventional nucleic acid synthesising machines, whereas PNA cannot.

In addition to non-conventional nucleic acids (such as LNA, PNA or nucleic acids containing base analogues), any one or more of the probes of use in the invention may comprise one or more destabilizing moieties.

The destabilizing moiety is a chemical entity which is generally unable to undergo base pairing and hydrogen bonding in the normal manner as usually occurs when complementary strands of nucleic acid become hybridised.

All manner of molecules may be suitable for use as a destabilizing moiety, although some compounds are specifically preferred, as described below. With the benefit of the present specification, the person skilled in the art will be able to test other compounds and readily select those which confer the appropriate degree of destabilization so as to prevent the hybridization of probes in the absence of target nucleic acid of interest. Particularly preferred, as a matter of convenience, are those compounds which are commercially available in a form (e.g. as phosphoramidites) which facilitates their incorporation into synthetic oligonucleotides using conventional automated solid phase nucleic acid synthesisers.

Destabilizing moieties which cannot base pair, but which nevertheless are capable of forming flexible folds and/or hairpin structures, are especially suitable. One such preferred destabilizing moiety comprises hexaethylene glycol (abbreviated herein as "Hex") (see Figure 5), which may be present singly or in tandem up to n times (where n can be any number 1, but conveniently has a maximum value of 5). In a particularly preferred embodiment, the third probe comprises one Hex molecule, where the number of bases opposite the destabilising moiety in the arm region of the first probe should be three to four bases. An alternative preferred destabilizing moiety comprises a plurality of

alkylene (especially methylene) repeats. Particularly preferred are penta- or hexamethylene spacers.

Other, less preferred, destabilizing moieties may alternatively be used. These include, but are not limited to, inosine, VirazoleTM (N[1]-[1- -D ribofuranosyl] 3-carboxamido-1,2,4-triazole), NebularinTM (N[9]-[1- -D ribofuranosyl]-purine), nitropyrrole, ribose, propyl or combinations of the above eg. propyl-Hex-propyl, propyl-Hex-Hex-propyl, etc. Propyl may be replaced by, for example, ethyl, butyl, pentyl, heptyl, octyl etc. The number of bases opposite the destabilizing moiety in the arm region of the reciprocal probe should be x , where x is an integer greater than or equal to 1. The exact number of bases will of course depend on the size of the destabilizing moiety and the value of n .

The following may be used as a guide: for each Hex molecule in the destabilizing moiety, the opposite probe should preferably comprise 3-4 bases (preferably 3) (i.e. X is between $3n$ and $4n$); for each other molecule or radical mentioned above present in the destabilizing moiety, the opposite probe should preferably comprise a single base, with the exception of the following: butyl - two bases, pentyl - two bases, heptyl - three bases, and octyl - four bases.

The chemicals described above and used as destabilizing moieties are all commercially available (e.g. from Glen Research, USA).

The person skilled in the art will appreciate how to select appropriate conditions, materials and sequences for the probes, in order to ensure that the complex of the first, second and third probes (and hence formation of the functional RNA promoter) occurs in a target dependent manner. In essence, the degree of complementarity between the arm regions of the first and second probes must be such that, in the conditions employed, they will not hybridise unless stabilised by hybridisation of the respective foot regions of the first and second probes to the target.

Generally therefore, the foot regions of the first and second probes will comprise at least 10 bases, preferably at least 20 bases, and more preferably at least 25 bases. There is no

upper limit on the size of the foot regions (which may, for example, comprise several kilobases). However, in practice, the probes will normally be *in vitro* synthesised oligonucleotides and so it will be preferred for the foot regions to comprise no more than about 75 bases.

In contrast, the number of complementary bases between the arm regions of the first and second probes will normally be no more than 25, typically less than 15, and optimally between 5 and 13 bases, such that the arm regions will not (under the assay conditions employed) become hybridised to each other in the absence of target.

In preferred embodiments, the invention provides a method of generating a signal in a target-dependent manner (i.e. creation of the complex and hence formation of the functional promoter) and causing amplification of this signal (generation of multiple RNA transcripts under the control of the promoter) in a system which may require the use of a single enzyme type (RNA polymerase), without the need for additional enzymes (e.g. DNA polymerases) to bring about the amplification. This is significant as the reaction conditions for optimum activity of RNA and DNA polymerases are generally mutually exclusive.

Detection Methods

RNA produced in accordance with the invention could be detected in a number of ways, optionally following amplification (most preferably by means of an isothermal amplification step e.g. as disclosed in US 5,399,491 and US 5,480,784). For example, newly-synthesised RNA could be detected in a conventional manner (e.g. by gel electrophoresis), with or without incorporation of labelled bases during the synthesis.

Alternatively, for example, newly-synthesised RNA could be captured at a solid surface (e.g. on a bead, or in a microtitre plate), and the captured molecule detected by hybridisation with a labelled nucleic acid probe (e.g. radio-labelled, or more preferably labelled with an enzyme, chromophore, fluorophore and the like). Preferred enzyme labels include horseradish peroxidase and alkaline phosphatase.

One preferred detection method involves the use of molecular beacons or the techniques of fluorescence resonance energy transfer ("FRET"), delayed fluorescence energy transfer ("DEFRET") or homogeneous time-resolved fluorescence ("HTRF"). Molecular beacons are molecules which a fluorescence signal may or may not be generated, depending on the conformation of the molecule. Typically, one part of the molecule will comprise a fluorophore, and another part of the molecule will comprise a "quencher" to quench fluorescence from the fluorophore. Thus, when the conformation of the molecule is such that the fluorophore and quencher are in close proximity, the molecular beacon does not fluoresce, but when the fluorophore and the quencher are relatively widely-separated, the molecule does fluoresce. The molecular beacon conveniently comprises a nucleic acid molecule labelled with an appropriate fluorophore and quencher.

One manner in which the conformation of the molecular beacon can be altered is by hybridisation to a nucleic acid, for example inducing looping out of parts of the molecular beacon. Alternatively, the molecular beacon may initially be in a hair-pin type structure (stabilised by self-complementary base-pairing), which structure is altered by hybridisation, or by cleavage by an enzyme or ribozyme.

FRET (Fluorescence Resonance Energy Transfer) occurs when a fluorescent donor molecule transfers energy via a nonradiative dipole-dipole interaction to an acceptor molecule. Upon energy transfer, which depends on the R^{-6} distance between the donor and acceptor, the donor's lifetime and quantum yield are reduced and the acceptor fluorescence is increased or sensitised.

Another approach (DEFRET, Delayed Fluorescence Energy Transfer) has been to exploit the unique properties of certain metal ions (Lanthanides e.g. Europium) that can exhibit efficient long lived emission when raised to their excited states (excitation = 337 nm, emission = 620 nm). The advantage of such long lived emission is the ability to use time resolved (TR) techniques in which measurement of the emission is started after an initial pause, so allowing all the background fluorescence and light scattering to dissipate. Cy5 (Amersham Pharmacia) (excitation = 620 nm, emission = 665 nm) can be used as the DEFRET partner.

HTRF (see WO92/01224; US 5,534,622) occurs where a donor (e.g. Europium) is encapsulated in a protective cage (cryptate) and attached to the 5' end of an oligomer. The acceptor molecule that has been developed for this system is a protein fluorophore, called XL665. This molecule is linked to the 3' end of a second probe. This system has been developed by Packard.

Amplification and detection of RNA or other nucleic acid molecules are further described in our prior patent applications WO 99/37805 and WO 99/37806.

In another embodiment, the newly-synthesised RNA, before or after amplification, results in formation of a ribozyme, which can be detected by cleavage of a particular nucleic acid substrate sequence (e.g. cleavage of a fluorophore/quencher dual-labelled oligonucleotide).

In a third aspect the invention provides a complex comprising three nucleic acid molecules: a target nucleic acid sequence; a first probe; and a second probe; wherein the first probe comprises, in the 5' to 3' direction, a template portion transcribable by an RNA polymerase, a template strand of an RNA polymerase promoter, and a target complementary portion which is hybridised to at least a 3' end region of the target sequence; and wherein the second probe is hybridised to the first probe adjacent or substantially adjacent to the 3' end of the target sequence, the second probe comprising part of the non-template strand complementary to the template strand of the promoter present in the first probe, the remaining part of the non-template strand of the promoter sequence being present at the 3' end of the target sequence; the arrangement being such that formation of the complex creates a functional double stranded RNA polymerase promoter with a discontinuity in the non-template strand, between the second probe and the target sequence.

Those skilled in the art will appreciate that both the second probe and the target sequence are required to hybridise to the first probe, in order to form the double stranded functional promoter. Accordingly, RNA transcripts of the template portion of the first probe are indicative of the presence in a sample of the target sequence. Thus the complex of the

third aspect of the invention provides the basis for an assay for detecting the presence in a sample of a nucleic acid sequence of interest.

In a fourth aspect therefore, the invention provides a method of detecting in a sample the presence of a nucleic acid sequence of interest; the method comprising the steps of: contacting a first and second probe as defined above, with the sample, so as to form the complex of the third aspect of the invention wherein the target sequence is the sequence of interest or is formed as a result of the presence in the sample of the sequence of interest; and detecting directly or indirectly RNA transcripts of the template portion of the first probe.

The target sequence may be RNA or DNA, and may be a sequence of interest, or may be formed as a result of the presence in the sample of the sequence of interest (e.g. by PCR, or by one of the processes disclosed in one of WO 93/06240, WO 94/29481, EP 0851033 or EP 0552931). The RNA transcript is conveniently amplified and detected by means of the methods described elsewhere in this specification.

In the complex of the third aspect of the invention, and the method of the fourth aspect of the invention, the discontinuity in the non-template strand of the promoter may, in principle, occur at any position (i.e. the 3' end of the target sequence may contribute any number of bases to the promoter sequence). In practice, it is preferred that the target sequence contributes between 1 and 5 bases, more preferably 3 bases, to the promoter sequence, such that the resulting promoter has optimal activity. It is also highly preferred that the second probe hybridises to the first probe immediately adjacent to the target sequence, so that the discontinuity in the non-template strand of the promoter is as small as possible. Again, this optimises promoter activity when the complex is formed.

The invention will now be further described by way of illustrative example and with reference to the accompanying drawings, wherein:

Figures 1 and 3 are schematic representations of a nucleic acid complex in accordance with the first aspect of the invention;

Figures 2, 4 and 6-9 are bar charts showing amount of RNA produced (in femtomoles) from various nucleic acid complexes;

Figure 5 is a schematic representation of a preferred destabilizing moiety for use in some embodiments of the invention; and

Figure 10 is a schematic representation of a nucleic acid complex in accordance with the third aspect of the invention.

Example 1

This example demonstrated that T7 RNA polymerase and three oligonucleotide probes could be used to detect a specific target sequence. Probe 1 ("template") contained, sequentially, a 34 base foot region complementary to the target sequence; an 8 base overlap sequence; the 17 base template strand of the T7 promoter; a +12 sequence and a capture and probe sequence for detection. Probe 2 ("complement") comprised a 31 base foot region complementary to the target sequence; an 8 base overlap sequence and the first three bases of the complementary (or non-template) strand of the T7 promoter. Probe 3 ("split complement") contained the remaining 14 bases of the complementary (or non-template) strand of the 17 base T7 promoter sequence. The example is illustrated schematically in Figure 1.

Referring to Figure 1, a complex formed by a hybridisation reaction comprises four nucleic acid molecules: a 120 base target sequence 2, a first probe 4 ("template"), a second probe ("complement") 6, and a third probe ("split complement") 8. The orientation (5' to 3') of the four molecules 2, 4, 6 and 8 is indicated.

The first probe/template 4 comprises, in the 5' to 3' direction: a template portion 4a which facilitates isolation and detection of RNA transcripts; a +12 sequence 4b to enhance promoter activity; a promoter sequence 4c which consists of 17 bases of the T7 promoter; an overlap region 4d to hybridise to a complementary portion 6b of the second probe/complement 6; and a foot region 4e comprising 34 bases to hybridise to a complementary portion of the target 2.

The second probe/complement 6, comprises in the 5' to 3' direction: a 31 base foot region 6a to hybridise to the target; an 8 base overlap region 6b to hybridise to the complementary portion 4d of the first probe 4; and a partial promoter region 6c consisting of the first three bases (TAA) of one strand of the T7 promoter.

The third probe 8, comprises the remaining 14 bases of the T7 promoter strand.

In the presence of target 2 and probe molecules 4, 6 and 8, a complex is formed in which the foot regions of first probe 4 and second probe 6 hybridise to the target in an adjacent or substantially adjacent manner, which in turn allows the complementary overlap portions 4d and 6b to hybridise. Hybridisation of the third probe 8 to the promoter sequence 4c of the first probe thus creates a functional, double stranded T7 promoter, one of the strands of which (formed by second and third probes 6 and 8) is discontinuous.

1.1 Preparation of oligonucleotides

All oligonucleotide probes were synthesised by phosphoramidite chemistry using an Applied Biosystems 380A synthesiser according to the manufacturer's instructions. Biotinylation of oligonucleotide probes was achieved by incorporation of a biotin phosphoramidite. Oligonucleotides functionalised with alkaline phosphatase were prepared using the manufacturers proprietary method (Oswel). All oligonucleotides were HPLC purified using standard techniques.

1.2 Synthesis of RNA off hybridised oligonucleotides

Hybridisation was achieved in an assay mixture that contained 10 fmol of probe 1, 50 fmol of probe 2, 25 fmol of probe 3 and 1 fmol of probe 4 (target for CFTR gene), together with T7 RNA polymerase buffer (Promega) (Promega; 40 mM Tris-HCl, pH 7.9, 6 mM MgCl₂, 2 mM spermidine, 10 mM NaCl at final concentration). The reaction volume was made up to 20 µl with RNase-free distilled water (allowing for later additions of enzymes and NTPs). Control reactions contained probes 1, 2 and 3 without target (probe 4). The mixture was heated to 90°C for 3 minutes to denature the nucleic acids, then cooled (by ramping at 0.1°C/second) to 37°C. T7 RNA polymerase (25 units) and 2 µl rNTP mix from Amersham Pharmacia Biotech (20 mM of each r NTP: adenosine 5'-triphosphate

(ATP), guanosine 5'-triphosphate (GTP), cytidine 5'-triphosphate (CTP) uridine 5'-triphosphate (UTP)) were added and the mixture incubated at 37°C for 3 hours.

1.3 Capture and detection of synthesised RNA

20 µl of assay sample was added to 145 µl hybridisation buffer (50 mM Tris-HCl, pH 8.0, 1 M NaCl, 20 mM EDTA and 0.1% BSA) containing 0.9 pmol biotinylated capture oligonucleotide (specific for the RNA to be detected) and 6 pmol specific alkaline phosphatase oligonucleotide in streptavidin coated wells. Incubation (60 minutes at room temperature, shaking at 300 rpm) allowed the RNA to be immobilised on the wells via the biotinylated capture probe and annealed to the detection probe. Unbound material was removed from the wells by washing four times with TBS/0.1% Tween-20, then once with alkaline phosphatase substrate buffer (Boehringer Mannheim). Finally, alkaline phosphatase substrate buffer containing 4-nitrophenyl phosphate (5mg/ml) was added to each well. The plate was incubated at 37°C in a Labsystems EIA plate reader and readings were taken at 405 nm every 2 minutes. Results are presented in Figure 2, which is a chart showing amount of RNA produced (in femtomoles), in the presence (+) or absence (-) of 1 fmol of target, for duplicate samples.

1.4 List of oligonucleotides

Probe 1 (template) Seq ID No. 15

5' TGCCTCCTTGTCTCCGTTCTGGATATCACCCGATGTGGCTCTCTCTCCCTA
TAGTGAGTCGTATTAATTTCTGAAGGTGTTTCCTATGATGAATATAGATACAGAA
GCG 3' (phosphate blocked)

Probe 2 (complement) Seq ID No. 16

5' GCCTGGCACCATTAAAGAAAATATCATCTTTTTCGAAATTAA 3'

Probe 3 (split complement) Seq ID No. 17

5' TACGACTCACTATA 3'

Probe 4 (target) Seq ID No. 18

5' GTTGGCATGCTTTGATGACGCTTCTGTATCTATATTCATCATAGGAAACAC
CAAAGATGATATTTTCTTTAATGGTGCCAGGCATAATCCAGGAAAACACTGAGAAC
AGAATGAAATTCTTC 3'

Sequence of transcribed RNA Seq ID No. 19

5' GGGAGAGAGAGCCACAUCGGGUGAUAUCCAGAACGGAGACAAGGAG
GCA 3'

Capture Probe Seq ID No. 20

5' TCTGCTGCCTGCTTGTCTGCGTTCT 3' (5' biotinylated)

Detection probe Seq ID No. 21

5' GGATATCACCCG 3' (3' alkaline phosphatase labelled)

Example 2

This example demonstrated that a Hexaethylene glycol linker (Hex) positioned 3 bases from the 3' end of Probe 3 (i.e. the split complement probe) increased the amount of signal obtained. The example is illustrated schematically in Figure 3. Corresponding integers are denoted using the same reference numerals adopted in Figure 1. H marks the approximate position of the hexaethylene residue incorporated in the split complement probe.

2.1 Preparation of oligonucleotides

All oligonucleotide probes were prepared and functionalised as described in Example 1.1. Hex incorporation was accomplished by reaction of the growing chain with 18-dimethoxytrityl hexaethylene glycol, 1-[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite. All oligonucleotides were HPLC purified using standard techniques.

The oligonucleotides used were identical to those described in Example 1, with the exception of the variant Probe 3 (split complement) oligo (referred to below as "Probe 5"), which contained a Hex between the 11th and 12th bases (counting from the 5' end).

2.2 Synthesis of RNA off hybridised oligonucleotides

Hybridisation was achieved in an assay mixture that contained 10 fmol of probe 1, 50 fmol of probe 2, 50 fmol of probe 3 or probe 5 (Hex containing variant of probe 3) and 1 fmol of probe 4 (target for CFTR gene), together with T7 RNA polymerase buffer (Promega). The reaction volume was made up to 20 μ l with RNase-free distilled water (allowing for later additions of enzymes and NTPs). Control reactions contained probes 1, 2 and 3, or probes 1, 2 and 5, without target (probe 4). The mixture was heated to 90°C for 3 minutes to denature the nucleic acids, then cooled (by ramping at 0.1°C / second) to 37°C. T7 RNA polymerase (25 units) and 2 μ l rNTP mix (Amersham Pharmacia Biotech) were added and the mixture incubated at 37°C for 3 hours.

2.3 Capture and detection of synthesised RNA

20 μ l of assay sample was processed as described in Example 1.3. Results are presented in Figure 4, which is a chart showing amount of RNA produced in the presence (+) or absence (-) of target, for complexes without ("No Hex") or with a hexaethylene residue in the split complement probe.

Example 3

This example demonstrated that increasing the length of the split complement probe at the 3' end by 1, 2 or 3 bases increased the amount of RNA signal observed.

3.1 Preparation of oligonucleotides

All oligonucleotide probes were prepared and purified as described in the preceding examples.

3.2 Synthesis of RNA off hybridised oligonucleotides

Hybridisation was achieved in an assay mixture that contained 10 fmol of probe 1, 50 fmol of probe 2, 50 fmol of probe 3 (14 base split complement), 4 (15 base split complement), 5 (16 base split complement) or 6 (17 base split complement) and 1 fmol of probe 7 (target for CFTR gene), together with T7 RNA polymerase buffer (Promega). All reactions also contained 50 ng salmon sperm DNA (Sigma) and 5% Polyethylene glycol 300 (Sigma). The reaction volume was made up to 20 µl with RNase-free distilled water (allowing for later additions of enzymes and NTPs). Control reactions contained probes 1, 2 and one of probes 4, 5 or 6, without target (probe 7). The mixture was heated to 90°C for 3 minutes to denature the nucleic acids, then cooled (by ramping at 0.1°C / second) to 37°C. After 1 hr, T7 RNA polymerase (Promega) (25 units) and 2 µl rNTP mix (Amersham Pharmacia Biotech).

3.3 Capture and detection of synthesised RNA

20 µl of assay sample was processed as described in Example 1.3. Results are presented in Figure 6, which is a chart showing amount of RNA produced in reactions having a split complement probe of 14, 15, 16 or 17 bases in length.

3.4 List of oligonucleotides

Probe 1 (template) (Seq ID No. 22)

5'TCGTCTTCCGGTCTCTCCTCTCAAGCCTCAGCGCTCTCTCTCCCTATAGTGAGT
CGTATTAATTTCTGAAGGTGTTTCCTATGATGAATATAGATACAGAAGCG 3'
(phosphate blocked)

Probe 2 (complement) – as Probe 2, Example 1

Probe 3 (14 base split complement) – as Probe 3, Example 1

Probe 4 (15 base split complement) – as Probe 3, Example 1 but with additional G at 3' end

Probe 5 (16 base split complement) – as Probe 3, Example 1 but with additional GG at 3' end

Probe 6 (17 base split complement) – as Probe 3, Example 1 but with additional GGG at 3' end

Probe 7 (target) – as Probe 4, Example 1

Sequence of transcribed RNA (Seq ID No. 23)

5' GGGAGAGAGAGCGCUGAGGCUUGAGAGAGACCGGAAGACGA 3'

Capture Probe (Seq ID No. 24)

5' TCTGCTCGTCTTCCGGTCTCTCCTC 3' (5' biotinylated)

Detection probe (Seq ID No. 25)

5' TCAAGCCTCAGC 3' (3' alkaline phosphatase)

Example 4

This example demonstrated that a three base deletion in a target sequence could be detected. The foot region of the complement probe was 30 bases whilst the foot region of the template probe was either 14 bases or 30 bases. The three base deletion was located 7 bases from the junction point on the template probe foot side of the junction.

4.1 Preparation of oligonucleotides

All oligonucleotide probes were prepared and purified as described previously. Octanediol was incorporated by reaction of the growing chain with 8-dimethoxytrityl octanediol, 1-[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite.

4.2 Synthesis of RNA off hybridised oligonucleotides

Hybridisation was achieved in an assay mixture that contained 10 fmol of probe 1 (14 base template foot), 50 fmol of probe 3, 50 fmol of probe 4 and 1 fmol of probe 5 (wild type

target sequence) or 1 fmol of probe 6 (mutant target sequence); 10 fmol of probe 2 (30 base template foot), 50 fmol of probe 3, 50 fmol of probe 4 and 1 fmol of probe 5 (wild type target sequence) or 1 fmol of probe 6 (mutant target sequence). All reactions also contained 50 ng salmon sperm DNA (Sigma) and 5 % Polyethylene glycol 300 (Sigma). T7 RNA polymerase buffer (Promega) was added. The reaction volume was made up to 20 µl with RNase-free distilled water (allowing for later additions of enzymes and NTPs). Control reactions excluded the target (probe 5 or 6). The mixture was heated to 90°C for 3 minutes to denature the nucleic acids, then cooled (by ramping at 0.1°C / second) to 37°C. After 1 hr, T7 RNA polymerase (Promega) (25 units) and 2 µl rNTP mix (Amersham Pharmacia Biotech) were added and the mixture incubated at 37°C for 3 hours.

4.3 Capture and detection of synthesised RNA

20 µl of assay sample was processed as described previously. Results are presented in Figure 7. Figure 7 shows the amount of RNA-produced for reactions in which the template comprised a 14 or 30 base foot region respectively ("A" and "B"), for wild type (i) or mutant (ii) target sequences, or controls (iii) with no target. The results demonstrate that it was readily possible to discriminate between the wild type and mutant targets.

4.4 List of oligonucleotides

Probe 1 (template probe with a 14 base foot region) (Seq ID No. 26)

5' TCGTCTTCCGGTCTCTCCTCTCAAGCCTCAGCGCTCTCTCTCCCTATAGTG
AGTCGTATTAATTTGAAQATATCATCTTTGGT 3' (phosphate blocked)

Q = Octanediol

Probe 2 (template probe with a 30 base foot region) (Seq ID No. 27)

5'TCGTCTTCCGGTCTCTCCTCTCAAGCCTCAGCGCTCTCTCTCCCTATAGTGAGT
CGTATTAATTTGAAQATATCATCTTTGGTGTTCCTATGATGAAT 3'

Q = Octanediol

Probe 3 (complement probe) (Seq ID No. 28)

5' GCCTGGCACCATTAAAGAAATTCGAAATTAA 3'

Probe 4 (split complement probe) – as Probe 4, Example 3

Probe 5 (wild type target sequence) – as Seq ID No. 18, Example 1

5' GTTGGCATGCTTTGATGACGCTTCTGTATCTATATTCATCATAGGAAACAC
CAAAGATGATATTTTCTTTAATGGTGCCAGGCATAATCCAGGAAAACCTGAGAAC
AGAATGAAATTCTTC 3'

Bold text represents the 3 bases that are deleted in the mutant.

Probe 6 (mutant target sequence) (Seq ID No. 29)



5'GATGACGCTTCTGTATCTATATTCATCATAGGAAACACCAATGATATTTTCTT
TAATGGTGCCAGG CAT AAT CCA GG 3'

[Arrow represents the position of the 3 base deletion. The 3 base deletion is located 7 bases from the junction.]

Sequence of transcribed RNA (as Seq ID No. 23, Example 3)

Capture Probe (as Seq ID No. 24, Example 3)

Detection probe (as Seq ID No. 25, Example 3)

Example 5

This example demonstrated that 23S rRNA in total RNA purified from *Escherichia coli* K12 could be detected.

5.1 Preparation of oligonucleotides

All oligonucleotide probes were prepared and purified as described previously.

5.2 Preparation of total RNA

E. coli was grown in Luria-Bertani medium (10 g l⁻¹ bacto-tryptone, 5 g l⁻¹ yeast extract and 10 g l⁻¹ sodium chloride) at 37 °C until the culture reached an OD₆₀₀ of 1.0. A Qiagen RNeasy® Mini Kit was used to purify the total RNA. Cells were harvested and lysed according to the manufacturer's instructions. RNA was quantified using GeneQuant II (Amersham Pharmacia Biotech) according to the manufacturer's instructions and aliquots were stored at -80 °C until ready for use.

5.3 Synthesis of RNA off hybridised oligonucleotides

Hybridisation was achieved in an assay mixture that contained 1 fmol of probe 1, 5 fmol of probe 2, 5 fmol of probe 3 and 10, 1 or 0.1 ng of total RNA from *E. coli* K12. 50 ng salmon sperm DNA (Sigma) and 5 % Polyethylene glycol 300 (Sigma) were also included in all reactions. T7 RNA polymerase buffer (Promega) was added and the reaction volume made up to 20 µl with RNase-free distilled water (allowing for later additions of enzymes and NTPs). Control reactions contained probes 1, 2 and 3 without any target RNA. The mixture was heated to 95 °C for 5 minutes and then cooled (by ramping at 0.1°C / second) to 37 °C. After 1 hr, T7 RNA polymerase (Promega) (25 units) and 2 µl rNTP mix (Amersham Pharmacia Biotech) were added and the mixture incubated at 37 °C for 3 hours. The reactions were stored at -80 °C.

5.4 Amplification of the RNA signal

To further amplify the RNA transcribed from the T7 promoter in the complex, a linear DNA template (probe 4) was used, which contained a single stranded T7 promoter sequence. A 10 µl aliquot of each reaction was added to a mix containing 20 fmol of probe 4, 8 µl T7 RNA polymerase buffer, 50 µM dNTPs, 2 mM rNTPs, 51 Units T7 RNA polymerase and 4 Units *Bst* DNA polymerase. The volume was made up to 40 µl with RNase-free distilled water.

The mixture was incubated at 37°C for 3 hours. The RNA from the initial reaction (5.3) hybridised with probe 4 and was extended by the Bst polymerase, forming a fully functional double stranded RNA promoter, which then produced multiple RNA transcripts of the second DNA template, probe 4.

5.5 Capture and detection of synthesised RNA

40 µl of assay sample was processed as described previously. Results are presented in Figure 8. Figure 8 shows the amount of RNA produced in reactions using varying amounts (10, 1 or 0.1ng) of total RNA from *E. coli* K12 as target, compared with a control reaction (no target).

5.6 List of oligonucleotides

Probe 1 (template probe) (Seq ID No. 30)

5' TCGTCTTCCGGTCTCTCCTCTCAAGCCTCAGCGCTCTCTCTCCCTATAGTG
AGTCGTATTAATTTTCGAAQGGCATGACAACCCGAACACCAGTGAT 3'

Q = Octanediol

Probe 2 (complement probe) (Seq ID No. 31)

5' GCATTTAGCTACCGGGCAGTGCCATTTTCGAAATTAA 3'

Probe 3 (split complement probe) – as Probe 4, Example 3

Probe 4 (2nd DNA template probe) - (Seq ID No. 32)

5' TGCCTGCTTGTCTGCGTTCTGGATATCACCCGAGTTCTCGCTTCCTATAGT
GAGTCGTATTAATTTCTCGTCTTCCQGGTCTCTCCTCTCAAGCCTCAGCGCTCTC
TCTCCC 3'

Q = Octanediol

Sequence of transcribed RNA to be detected (Seq ID No. 33)

5' GGAAGCGAGAACUCGGGUGAUAUCCAGAACGCAGACAAGCAGGCA 3'

Capture Probe – as Seq ID No. 20, Example 1

Detection probe – as Seq ID No. 21, Example 1

Example 6

This example demonstrated that a T3 promoter and T3 RNA polymerase could be used instead of a T7 promoter and T7 RNA polymerase. A 14 base split complement probe was used for the 17 base T3 promoter.

6.1 Preparation of oligonucleotides

All oligonucleotide probes were prepared and purified as described previously.

6.2 Synthesis of RNA off hybridised oligonucleotides

For the assay containing a T7 promoter, 10 fmol probe 1, 50 fmol probe 2, 50 fmol probe 3 and 1 fmol probe 4 were used. For the assay containing a T3 promoter, 10 fmol probe 5, 50 fmol probe 6, 50 fmol probe 7 and 1 fmol probe 4 were used. 50 ng salmon sperm DNA (Sigma) and 5% Polyethylene glycol 300 (Sigma) were also included in all reactions. T7 RNA polymerase buffer (Promega) was used with both T7 (Promega) and T3 RNA polymerases (Promega) and the reaction volume made up to 20 µl with RNase-free distilled water (allowing for later additions of enzymes and NTPs). Control reactions contained probes 1, 2 and 3 or probes 5, 6 and 7. The mixture was heated to 90°C for 3 minutes and then cooled (by ramping at 0.1°C/second) to 37°C. After 1 hr, T7 RNA polymerase (25 units) or T3 RNA polymerase (25 units) and 2 µl rNTP mix (Amersham Pharmacia Biotech) were added and the mixture incubated at 37°C for 3 hours. The reactions were stored at -80°C.

6.3 Capture and detection of synthesised RNA

20 µl of assay sample was processed as described previously. Results are presented in Figure 9.

Figure 9 shows the amount of RNA produced in reactions using T7 or T3 RNA polymerase. As expected, the reaction was specific in that T7 RNA polymerase would only produce RNA from a T7 promoter, not from a T3 promoter; and vice versa for T3 RNA polymerase. T3 polymerase produced slightly more RNA than T7 polymerase but, in this system, the background signal (in the absence of target) was much higher for T3.

List of oligonucleotides

Probe 1 (T7 template) (Seq ID No. 34)

5' TCGTCTTCCGGTCTCTCCTCTCAAGCCTCAGCCTTCTCTCTTCCTATAGTG
AGTCGTATTAATTTCTGAAGGTGTTTCCTATGATGAATATAGATACAGAAGCG 3'

Probe 2 (T7 complement) – as Seq ID No. 16, Example 1

Probe 3 (T7 split complement) – as Seq ID No. 17, Example 1

Probe 4 (target) (Seq ID No. 35)

5'CCTCCTCTAGTTGGCATGCTTTGATGACGCTTCTGTATCTATATTCATCAT
AGGAAACACCAAAGATGATATTTTCTTTAATGGTGCCAGGCATAATCCAGGAAA
ACTGAGAACAGAATGA 3'

Probe 5 (T3 template) (Seq ID No. 36)

5'TCGTCTTCCGGTCTCTCCTCTCAAGCCTCAGCCTTCTCTCTTCCTTTAG
TGAGGGTTAATTATTTCTGAAGGTGTTTCCTATGATGAATATAGATACAGAAGCG
3'

Probe 6 (T3 complement) (Seq ID No. 37)

5' GCCTGGCACCATTAAAGAAAATATCATCTTTTTCGAAATAAT 3'

Probe 7 (T3 split complement) (Seq ID No. 38)

5' TAACCCTCACTAAA 3'

Sequence of transcribed RNA (Seq ID No. 39)

5' GGAA GAG AGA AGG CUG AGG CUU GAGAGGAGAGACCGGAAGACGA 3'

Capture Probe – as Seq ID No. 24, Example 3

Detection probe – as Seq ID No. 25, Example 3

Example 7

This example illustrates the complex of the third aspect of the invention, by reference to Figure 10.

Referring to Figure 10, a complex comprises a first probe 20, a second probe 22 and a target nucleic acid 24. The first probe 20 comprises a transcribable portion 20a, a template strand 20b of an RNA polymerase promoter (such as the T3, T7 or SP6 RNA promoter), and a target complementary portion 20c which is hybridised to 3' end of the target sequence 24.

The second probe 22 is hybridised to the first probe 20 adjacent to the target sequence 24. The second probe 22 comprises bases which are complementary to part (preferably the majority, e.g. 13-15 bases) of the template strand of the promoter on first probe 20 (i.e. the second probe 22 comprises part, preferably the majority, of the non-template strand of the promoter). The remainder of the non-template strand (typically 4-2 bases) is contributed by the 3' end of the target sequence 24. Accordingly, the complex is such that it comprises a functional double stranded RNA polymerase promoter which, in the

presence of a relevant RNA polymerase and ribonucleotide triphosphates, causes synthesis of RNA transcripts 26 of the template portion 20a of the first probe.

The RNA transcripts 26 may be detected, preferably following an optional amplification step, to indicate the presence of the target sequence 24, which may be the sequence of interest or which may have been generated in turn by the presence of the sequence of interest (e.g. by PCR, or by means of one of the other processes described in the prior art, such as WO 93/06240, WO 94/29481 or EP 0851033).

Claims

1. A complex formed by a hybridisation reaction comprising four nucleic acid molecules; the complex comprising a target nucleic acid molecule and first, second and third nucleic acid probe molecules; wherein the first probe comprises a foot region which is complementary to a first portion of the target and is hybridised thereto, and an arm region which is substantially non-complementary to the target; the second probe comprises a foot region which is complementary to a second portion of the target, such that the foot region of the second probe is hybridised to the target adjacent or substantially adjacent to the foot region of the first probe, the second probe also comprising an arm region which is substantially non-complementary to the target but which is complementary and hybridised to the arm region of the first probe; the third probe being complementary, at least in part, to a portion of the arm region of the first probe, such that the third probe is hybridised to the arm region of the first probe adjacent or substantially adjacent to the second probe; and wherein formation of the complex creates a functional double-stranded RNA polymerase promoter, one strand of the promoter being provided by the first probe, and the other strand being provided jointly by the second probe and by the third probe.
2. A complex according to claim 1, wherein at least one of the first, second or third probes comprises PNA and/or LNA.
3. A complex according to claim 2, wherein the first and/or second probe comprises PNA and/or LNA.
4. A complex according to any one of claims 1, 2 or 3, comprising a functional double stranded T3, T7 or SP6 RNA polymerase promoter.

5. A complex according to any one of the preceding claims, comprising single or double stranded sequence adjacent to the promoter which increases the activity of the promoter.
6. A complex according to claim 5, wherein one of said probes comprises a +12 sequence.
7. A complex according to claim 5, wherein the first probe comprises a +12 sequence.
8. A complex according to any one of the preceding claims, comprising a sequence which, when transcribed into RNA, facilitates isolation, identification, detection, quantification or amplification of the transcript.
9. A complex according to any one of the preceding claims, wherein one of said probes comprises a destabilizing moiety.
10. A complex according to any one of the preceding claims, wherein the second and third probes form a discontinuous sequence of an RNA polymerase promoter template strand.
11. A complex according to any one of claims 1-9, wherein the second and third probes form a discontinuous sequence of an RNA polymerase promoter non-template strand.
12. A method of detecting the presence of a target nucleic acid molecule in a sample, the method comprising the steps of: contacting the sample comprising the target with first and second nucleic acid probes, each probe comprising a foot region complementary to respective first and second portions of the target, which portions are adjacent or substantially so; wherein the first and second probes each further comprise an arm region substantially non-complementary to the target, at least part of the arm region of

the first probe being complementary to at least part of the arm region of the second probe, such that respective foot regions of the first and second probes hybridise to the target, allowing hybridisation of the complementary parts of the arm regions of the first and second probes; and causing to be present a third nucleic acid probe molecule which is complementary to a portion of the arm region of the first probe, such that the third probe hybridises to the first probe adjacent or substantially adjacent to the arm region of the second probe, thereby creating a functional double-stranded RNA polymerase promoter, one strand of the promoter being provided by the first probe, the other strand being provided jointly by the second and third probes; causing RNA synthesis from the RNA promoter; and detecting, directly or indirectly, the RNA so synthesised.

13. A method according to claim 12, performance of which results in the formation of a complex in accordance with any one of claims 1-11.
14. A method according to claim 12 or 13, wherein RNA produced from the functional RNA promoter is amplified prior to detection.
15. A method according to any one of claims 12, 13 or 14, wherein RNA produced from the functional RNA promoter is detected directly or indirectly via a method which involves use of a molecular beacon or fluorophore.

A complex comprising three nucleic acid molecules: a target nucleic acid sequence; a first probe; and a second probe; wherein the first probe comprises, in the 5' to 3' direction, a template portion transcribable by an RNA polymerase, and a template strand of an RNA polymerase promoter, a target complementary portion which is hybridised to at least a 3' end region of the target sequence; and wherein the second probe is hybridised to the first probe adjacent or substantially adjacent to the 3' end of the target sequence, the second probe comprising part of the non-template strand complementary to the template strand of the promoter present in the first probe, the remaining part of the non-template strand of the promoter sequence being present at the 3' end of the target sequence; the arrangement being such that formation of the complex creates a functional double stranded RNA polymerase promoter, with a discontinuity in the non-template strand, between the second probe and the target sequence.

16. A method of detecting in a sample the presence of a nucleic acid target sequence; the method comprising the steps of: contacting a first and second probe as defined above, with the sample, so as to form the complex of claim 16; and detecting directly or indirectly RNA transcripts of the template portion of the first probe.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau




(43) International Publication Date
8 February 2001 (08.02.2001)

PCT

(10) International Publication Number
WO 01/09377 A1

- (51) **International Patent Classification⁷:** C12Q 1/68
- (21) **International Application Number:** PCT/GB00/02962
- (22) **International Filing Date:** 31 July 2000 (31.07.2000)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
9917813.9 ✓ 29 July 1999 (29.07.1999) GB
60/149,176 ✓ 17 August 1999 (17.08.1999) US
- (71) **Applicant (for all designated States except US):** CYTO-CELL LIMITED [GB/GB]; Unit 6, Somerville Court, Trinity Way, Adderbury, Banbury, Oxfordshire OX17 3SN (GB).
- (72) **Inventors; and**
- (75) **Inventors/Applicants (for US only):** LLOYD, John, Scott [GB/GB]; 14 Windsor Close, King Sutton, Oxfordshire OX17 3QT (GB). WESTON, Anthony [GB/GB];
- 8 New Court, Dorchester Close, Northolt, Middlesex UB5 4PF (GB). **CARDY, Donald, Leonard, Nicholas** [GB/GB]; Trinlan, Blacksmith's Lane, Aston-le-Walls, Northamptonshire NN11 6UN (GB).
- (74) **Agent:** KEITH W NASH & CO; 90-92 Regent Street, Cambridge CB2 1DP (GB).
- (81) **Designated States (national):** AU, CA, JP, US.
- (84) **Designated States (regional):** European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
- Published:**
— *With international search report.*
— *Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.*
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: METHOD FOR DETECTING NUCLEIC ACID TARGET SEQUENCES INVOLVING IN VITRO TRANSCRIPTION FROM AN RNA POLYMERASE PROMOTER



(57) Abstract: Disclosed is a complex formed by a hybridisation reaction comprising four nucleic acid molecules; the complex comprising a target nucleic acid molecule and first, second and third nucleic acid probe molecules; wherein the first probe comprises a foot region which is complementary to a first portion of the target and is hybridised thereto, and an arm region which is substantially non-complementary to the target; the second probe comprises a foot region which is complementary to a second portion of the target, such that the foot region of the second probe is hybridised to the target adjacent or substantially adjacent to the foot region of the first probe, the second probe also comprising an arm region which is substantially non-complementary to the target but which is complementary and hybridised to the arm region of the first probe; the third probe being complementary, at least in part, to a portion of the arm region of the first probe, such that third probe is hybridised to the arm region of the first probe adjacent or substantially adjacent to the second probe; and wherein formation of the complex creates a functional double-stranded RNA polymerase promoter, one strand of the promoter being provided by the first probe, and the other strand being provided jointly by the sec-

ond probe and by the third probe; and a method of detecting a target nucleic acid sequence of interest which method involves the formation of the complex.

WO 01/09377 A1





Fig. 1

2 / 10

*Fig. 2*

3 / 10




Fig. 3

4 / 10




Fig. 4

5 / 10




Fig. 5

6 / 10




Fig. 6

7 / 10




Fig. 7

8 / 10




Fig. 8




Fig. 9

10 / 10




Fig. 10

COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEYU.S. DEPARTMENT OF COMMERCE
Patent and Trademark Office

ATTORNEY DOCKET NO.: 056222-5009

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

**METHOD FOR DETECTING NUCLEIC ACID TARGET SEQUENCES INVOLVING IN VITRO
TRANSCRIPTION FROM AN RNA POLYMERASE PROMOTER**

the specification of which:

is attached hereto; or

was filed as United States application Serial No. _____ on _____ and was amended on _____ (if applicable); or

was filed as PCT international application Number PCT/GB00/02962 on 31 July 2000, as amended under PCT Article 19
on _____ (if applicable).I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by
any amendment referred to above.I acknowledge the duty to disclose to the U.S. Patent and Trademark Office information which is material to the patentability of claims
presented in this application in accordance with Title 37, Code of Federal Regulations, 1.56.I hereby claim foreign priority benefits under Title 35, United States Code, 119(a)-(d) or 365(b) of any foreign application(s) for patent
or inventor's certificate or 365(a) of any PCT international application(s) designating at least one country other than the United States of
America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international
application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a
filing date before that of the application(s) of which priority is claimed:**PRIOR FOREIGN APPLICATION(S):**

COUNTRY (if PCT, indicate PCT)	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED
Great Britain	9917813.9	29 July 1999	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No

Combined Declaration For Patent Application and Power of Attorney - (Continued)
(includes Reference to PCT International Applications)
ATTORNEY DOCKET NO.: 056222-5009

I hereby claim the benefits under Title 35, United States Code 119(e) of any United States provisional application(s) listed below.

U.S. PROVISIONAL APPLICATIONS

U.S. PROVISIONAL APPLICATION NO.

U.S. FILING DATE

60/149,176

17 August 1999

I hereby claim the benefit under Title 35, United States Code, 120 of any United States application(s) or 365(c) of any PCT international application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of Title 35, United States Code, 112, I acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to me to be material to the patentability of claims presented in this application in accordance with Title 37, Code of Federal Regulations, 1.56 which became available between the filing date of the prior application(s) and the national or PCT international filing date of this application:

PRIOR U.S. APPLICATIONS OR PCT INTERNATIONAL APPLICATIONS DESIGNATING THE U.S. FOR BENEFIT:

U.S. APPLICATIONS		STATUS (Check One)		
U.S. APPLICATION NO.	U.S. FILING DATE	PATENTED	PENDING	ABANDONED

POWER OF ATTORNEY: As a named inventor, I hereby appoint the registered practitioners of Morgan, Lewis & Bockius LLP included in the Customer Number provided below to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and direct that all correspondence be addressed to that Customer Number.

Customer Number: 009629

Direct Telephone Calls To:
(name and telephone number)

Elizabeth C. Weimar
202-739-5812

Combined Declaration For Patent Application and Power of Attorney - (Continued)
 (Includes Reference to PCT International Applications)
 ATTORNEY-DOCKET NO.: 056222-5009

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

FULL NAME OF SOLE OR FIRST INVENTOR	<u>John Scott Lloyd</u>	
RESIDENCE & CITIZENSHIP	14 Windsor Close, King Sutton, Oxfordshire OX17 3QT, Great Britain <u>COBX</u>	COUNTRY OF CITIZENSHIP Great Britain
POST OFFICE ADDRESS	14 Windsor Close, King Sutton, Oxfordshire OX17 3QT, Great Britain	
FIRST OR SOLE INVENTOR'S SIGNATURE	<u>X</u> <u>John Scott Lloyd</u>	DATE <u>X</u> 26/1/02

FULL NAME OF SECOND INVENTOR	<u>Anthony Weston</u>	
RESIDENCE & CITIZENSHIP	8 New Court, Dorchester Close, Northolt, Middlesex UB5 4PF, Great Britain <u>COBX</u>	COUNTRY OF CITIZENSHIP Great Britain
POST OFFICE ADDRESS	8 New Court, Dorchester Close, Northolt, Middlesex UB5 4PF, Great Britain	
SECOND INVENTOR'S SIGNATURE	<u>X</u> <u>Anthony Weston</u>	DATE <u>X</u> 1/2/2002

FULL NAME OF THIRD INVENTOR	<u>Donald Leonard Nicholas Cardy</u>	
RESIDENCE & CITIZENSHIP	Trinlan, Blacksmith's Lane, Aston-le-Walls, Northhamptonshire NN11 6UN, Great Britain <u>COBX</u>	COUNTRY OF CITIZENSHIP Great Britain
POST OFFICE ADDRESS	Trinlan, Blacksmith's Lane, Aston-le-Walls, Northhamptonshire NN11 6UN, Great Britain	
THIRD INVENTOR'S SIGNATURE	<u>X</u> <u>Donald Leonard Nicholas Cardy</u>	DATE <u>X</u> 24/1/02

Listing of Inventors Continued on attached page(s) ☐ Yes ☒ No

SEQUENCE LISTING

<110> CytoCELL Limited

<120> Improvements in or Relating to Nucleic Acid Assays

<130> MJL/C1092'1/C

<140>

<141>

<160> 39

<170> PatentIn Ver. 2.1

<210> 1

<211> 18

<212> DNA

<213> Bacteriophage T3

<400> 1

aaattaaccc tcactaaa

18

<210> 2

<211> 18

<212> DNA

<213> Bacteriophage T3

<400> 2

ttattaaccc tcactaaa

18

<210> 3

<211> 17

<212> DNA

<213> Bacteriophage T7

<400> 3

taatacgact cactata

17

<210> 4

<211> 17

<212> DNA

<213> Bacteriophage SP6

<400> 4

atttaggtga cactata

17

```
<210> 5
<211> 12
<212> DNA
<213> Artificial Sequence
```

<220>
<223> Description of Artificial Sequence:synthetic
oligonucleotide

```
<400> 5
atcgtcagtc cc
```

12

```
<210> 6
<211> 12
<212> DNA
<213> Artificial Sequence
```

<223> Description of Artificial Sequence: synthetic oligonucleotide

```
<400> 6
gctctctctc cc
```

12

```
<210> 7
<211> 12
<212> DNA
<213> Artificial Sequence
```

<220>
<223> Description of Artificial Sequence: synthetic oligonucleotide

```
<400> 7
atcctctctc cc
```

12

```
<210> 8
<211> 12
<212> DNA
<213> Artificial Sequence
```

<220>

WO 01/09377

PCT/GB00/02962

<223> Description of Artificial Sequence: synthetic
oligonucleotide

<400> 8

gttctctctc cc

12

<210> 9

<211> 12

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic
oligonucleotide

<400> 9

gatgtgtctc cc

12

<210> 10

<211> 12

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic
oligonucleotide

<400> 10

gttggtgtctc cc

12

<210> 11

<211> 12

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic
oligonucleotide

<400> 11

atcctcgtgc cc

12

<210> 12

<211> 12

WO 01/09377

PCT/GB00/02962

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic
oligonucleotide

<400> 12

gctctcgtgc cc

12

<210> 13

<211> 12

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic
oligonucleotide

<400> 13

gttctcgtgc cc

12

<210> 14

<211> 12

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic
oligonucleotide

<400> 14

gttgtggtgc cc

12

<210> 15

<211> 108

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic
oligonucleotide

<400> 15

tgccctcttg tctccgttct ggatatacacc cgatgtggct ctctctccct atagtgagtc 60

WO 01/09377

PCT/GB00/02962

gtattaattt cgaaggtgtt tcctatgatg aatatagata cagaagcg

108

<210> 16

<211> 42

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic
oligonucleotide

<400> 16

gcctggcacc attaaagaaa atatcatctt tttcgaaatt aa

42

<210> 17

<211> 14

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic
oligonucleotide

<400> 17

tacgactcac tata

14

<210> 18

<211> 120

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic
oligonucleotide

<400> 18

gttggcatgc tttgatgacg cttctgtatc tatattcatc ataggaaaca ccaaagatga 60
tattttcttt aatggtgccg ggcataatcc aggaaaactg agaacagaat gaaattcttc 120

<210> 19

<211> 49

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: RNA transcript
of synthetic oligonucleotide

<400> 19

gggagagaga gccacaucgg gugauaucca gaacggagac aaggaggca

49

<210> 20

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic oligonucleotide

<400> 20

tctgctgcct gcttgtctgc gttct

25

<210> 21

<211> 12

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic oligonucleotide

<400> 21

ggatatcacc cg

12

<210> 22

<211> 103

<212> DNA

<213> Artificial Sequence

$\langle 220 \rangle$

<223> Description of Artificial Sequence: synthetic oligonucleotide

<400> 22

```
t c g t c t t c c g   g t c t c t c t c   t c a a g c c t c a   g c g c t c t c t c   t c c c t a t a g t   g a g t c g t a t t   60
a a t t t c q a a g   g t g t t t c c t a   t g a t g a a t a t   a g a t a c a g a a   g c g                                     103
```

103

<210> 23
<211> 44
<212> RNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: RNA transcript
of synthetic oligonucleotide

<400> 23

gggagagaga gcgcugaggc uugagaggag agaccggaag acga

<210> 24
<211> 25
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic
oligonucleotide

<400> 24

tctgctcgtc ttccggtctc tcttc

<210> 25
<211> 12
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic
oligonucleotide

<400> 25

tcaagcctca gc

<210> 26
<211> 83
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic
oligonucleotide

WO 01/09377

PCT/GB00/02962

<400> 26

tcgtcttccg gtctctcttc tcaagcctca gcgctctctc tccctatagt gagtcgtatt 60
aatttcgaaa tatcatcttt ggt 83

<210> 27

<211> 99

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic
oligonucleotide

<400> 27

tcgtcttccg gtctctcttc tcaagcctca gcgctctctc tccctatagt gagtcgtatt 60
aatttcgaaa tatcatcttt ggtgtttcct atgatgaat 99

<210> 28

<211> 31

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic
oligonucleotide

<400> 28

gcctggcacc attaaagaaa ttcgaaatta a 31

<210> 29

<211> 77

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic
oligonucleotide

<400> 29

gatgacgctt ctgtatctat attcatcata ggaaacacca atgatatttt cttaaagggt 60
gccaggcata atccagg 77

<210> 30

<211> 95

WO 01/09377

PCT/GB00/02962

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic
oligonucleotide

<400> 30

tcgtcttccg gtctctcctc tcaagcctca gcgctctctc tccctatagt gagtcgtatt 60
aatttcgaag gcatgacaac ccgaacacca gtgat 95

<210> 31

<211> 37

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic
oligonucleotide

<400> 31

gcatttagct accgggcagt gccattttcg aaattaa 37

<210> 32

<211> 111

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic
oligonucleotide

<400> 32

tgcctgcttg tctgcgttct ggatatcacc cgagttctcg ctctctatag tgagtcgtat 60
taatttctcg tcttcgggtc tctcctctca agcctcagcg ctctctctcc c 111

<210> 33

<211> 45

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: RNA transcript
of synthetic oligonucleotide

WO 01/09377

PCT/GB00/02962

<400> 33

ggaagcgaga acucggguga uauccagaac gcagacaagc aggca

45

<210> 34

<211> 103

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic
oligonucleotide

<400> 34

tcgtcttcgc gtctctctc tcaagcctca gccttctctc ttcttatagt gagtcgtatt 60
aatttcgaag gtgtttccta tgatgaatat agatacagaa gcg 103

<210> 35

<211> 121

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic
oligonucleotide

<400> 35

cctcctctag ttggcatgct ttgatgacgc ttctgtatct atattcatca taggaaacac 60
caaagatgat attttcttta atggtgccag gcataatcca ggaaaactga gaacagaatg 120
a 121

<210> 36

<211> 103

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic
oligonucleotide

<400> 36

tcgtcttcgc gtctctctc tcaagcctca gccttctctc ttcttttagt gaggggtaat 60
tatttcgaag gtgtttccta tgatgaatat agatacagaa gcg 103

<210> 37

WO 01/09377

PCT/GB00/02962

<211> 42

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic
oligonucleotide

<400> 37

gcctggcacc attaaagaaa atatcatctt tttcgaaata at

42

<210> 38

<211> 14

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic
oligonucleotide

<400> 38

taaccctcac taaa

14

<210> 39

<211> 44

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: RNA transcript
of synthetic oligonucleotide

<400> 39

ggaagagaga aggcugaggc uugagaggag agaccggaag acga

44